Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rawlins: from NICE to new key body?

This article was originally published in Clinica

Executive Summary

Professor Sir Michael Rawlins, who until last month chaired the UK’s National Institute for Health and Care Excellence (NICE) for 13 years (www.clinica.co.uk, 2 April 2013), is rumored to have been tapped to head one of the NHS’s incipient Academic Health Science Networks (AHSN), according to a Clinica source. A total of 15 AHSNs are planned for England – these networks will act as forums for NHS academia, industry and other stakeholders to collaborate on best practice and getting innovation into the health system (www.clinica.co.uk, 9 May 2013). Having someone with Prof Rawlins’ long background in HTA on board to head an AHSN would significantly raise the profile of these organizations and underline the key role that they are expected to play in the innovation-pushing machinery of the new NHS (www.clinica.co.uk, 18 March 2013).

You may also be interested in...



Regulatory Measures Could Mitigate Coronavirus Risks In Europe

As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.

Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches

Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020

Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

Topics

UsernamePublicRestriction

Register

MT100358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel